Histological effects of givinostat in boys with Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 26, Issue 10, 2016, Pages 643-649

  Bettica, Paolo ^a   Petrini, Stefania ^b   D'Oria, Valentina ^b   D'Amico, Adele ^b   Catteruccia, Michela ^b   Pane, Marika ^c   Sivo, Serena ^c   Magri, Francesca ^d   Brajkovic, Simona ^d   Messina, Sonia ^e,f   Vita, Gian Luca ^f   Gatti, Barbara ^a   Moggio, Maurizio ^d   Puri, Pier Lorenzo ^g,h   Rocchetti, Maurizio ⁱ   De Nicolao, Giuseppe ^j   Vita, Giuseppe ^e,f   Comi, Giacomo P ^d   Bertini, Enrico ^b   Mercuri, Eugenio ^c  

^a Italfarmaco SpA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f Fondazione Aurora Onlus   (Italy)

^g BURNHAM INSTITUTE   (United States)

^h IRCCS FONDAZIONE SANTA LUCIA   (Italy)

ⁱ Poggibonsi (SI)   (Italy)

^j UNIVERSITY OF PAVIA   (Italy)

more..

Author keywords

Clinical trial; Duchenne muscular dystrophy; Givinostat; Histology; Histone deacetylase inhibitor

Indexed keywords

GIVINOSTAT; CARBAMIC ACID DERIVATIVE; CORTICOSTEROID; HISTONE DEACETYLASE INHIBITOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERANCE; DUCHENNE MUSCULAR DYSTROPHY; FRACTIONATION; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MUSCLE TISSUE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TISSUE NECROSIS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MOTOR ACTIVITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; SKELETAL MUSCLE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CARBAMATES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PLATELET COUNT; TREATMENT OUTCOME;

EID: 84991089487     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2016.07.002     Document Type: Article

References (22)

1. [1] Mendell, J.R., Shilling, C., Leslie, N.D., et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:3 (2012), 304–313.
2. [2] Colussi, C., Mozzetta, C., Gurtner, A., et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 105:49 (2008), 19183–19187.
3. [3] Consalvi, S., Mozzetta, C., Bettica, P., et al. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med 19 (2013), 79–87.
4. [4] Minetti, G.C., Colussi, C., Adami, R., et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 12:10 (2006), 1147–1150.
5. [5] Laboratories ATSCoPSfCPF, ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:1 (2002), 111–117.
6. [6] Mayhew, A., Mazzone, E.S., Eagle, M., et al. Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55:11 (2013), 1038–1045.
7. [7] Mercuri, E., McDonald, C., Mayhew, A., et al. International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15–16 February 2012. Neuromuscul Disord 22:11 (2012), 1025–1028.
8. [8] Desguerre, I., Mayer, M., Leturcq, F., Barbet, J.P., Gherardi, R.K., Christov, C., Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 68:7 (2009), 762–773.
9. [9] Cirak, S., Arechavala-Gomeza, V., Guglieri, M., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:9791 (2011), 595–605.
10. [10] Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:5 (2013), 637–647.
11. [11] Peverelli, L., Testolin, S., Villa, L., et al. Histological muscular history in Duchenne Dystrophy patients with and without steroid treatment. Neurology 85:21 (2015), 1886–1893.
12. [12] Forbes, S.C., Willcocks, R.J., Triplett, W.T., et al. Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study. PLoS ONE, 9(9), 2014, e106435.
13. [13] Iezzi, S., Di Padova, M., Serra, C., et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 6:5 (2004), 673–684.
14. [14] Mendell, J.R., Sahenk, Z., Malik, V., et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 23:1 (2015), 192–201.
15. [15] Nakatani, M., Takehara, Y., Sugino, H., et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 22:2 (2008), 477–487.
16. [16] Tsuchida, K., Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol 27 (2008), 14–18.
17. [17] Subramanian, S., Bates, S.E., Wright, J.J., Espinoza-Delgado, I., Piekarz, R.L., Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3:9 (2010), 2751–2767.
18. [18] Pane, M., Mazzone, E.S., Sivo, S., et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS ONE, 9(10), 2014, e108205.
19. [19] McDonald, C.M., Henricson, E.K., Abresch, R.T., et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48:3 (2013), 343–356.
20. [20] Mazzone, E.S., Pane, M., Sormani, M.P., et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS ONE, 8(1), 2013, e52512.
21. [21] Dubowitz, V.S., Sewry, C.A., Oldfords, A., Muscle biopsy: a practical approach. 4th ed, 2013, Saunders Ltd., London.
22. [22] Wang, J.F., Forst, J., Schroder, S., Schroder, J.M., Correlation of muscle fiber type measurements with clinical and molecular genetic data in Duchenne muscular dystrophy. Neuromuscul Disord 9:3 (1999), 150–158.